scholarly journals FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas

Sarcoma ◽  
2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Matthias R. Benz ◽  
Johannes Czernin ◽  
William D. Tap ◽  
Jeffrey J. Eckardt ◽  
Leanne L. Seeger ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Metabolic Response ◽  
Neoadjuvant Treatment ◽  
Bone Sarcoma ◽  
Ct Imaging ◽  
Histopathologic Response ◽  
Pet Ct ◽  
Bone Sarcomas ◽  
Primary Bone ◽  
Fdg Pet Ct

Purpose. The aim of this study was to prospectively evaluate whether FDG-PET allows an accurate assessment of histopathologic response to neoadjuvant treatment in adult patients with primary bone sarcomas.Methods. Twelve consecutive patients with resectable, primary high grade bone sarcomas were enrolled prospectively. FDG-PET/CT imaging was performed prior to the initiation and after completion of neoadjuvant treatment. Imaging findings were correlated with histopathologic response.Results. Histopathologic responders showed significantly more pronounced decreases in tumor FDG-SUVmax from baseline to late follow up than non-responders (64±19% versus29±30%, resp.;P=.03). Using a 60% decrease in tumor FDG-uptake as a threshold for metabolic response correctly classified 3 of 4 histopathologic responders and 7 of 8 histopathologic non-responders as metabolic responders and non-responders, respectively (sensitivity, 75%; specificity, 88%).Conclusion. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients.

Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer

2009 ◽  
Vol 36 (1) ◽  
pp. 38-45 ◽  
Author(s):  
Luca Guerra ◽  
Rita Niespolo ◽  
Giuseppe Di Pisa ◽  
Davide Ippolito ◽  
Elena De Ponti ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Glucose Metabolism ◽  
Fdg Pet ◽  
Neoadjuvant Treatment ◽  
Histopathologic Response ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype

Radiology ◽  
2015 ◽  
Vol 277 (2) ◽  
pp. 358-371 ◽  
Author(s):  
David Groheux ◽  
Mohamed Majdoub ◽  
Alice Sanna ◽  
Patricia de Cremoux ◽  
Elif Hindié ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Breast Cancer Subtype ◽  
Neoadjuvant Treatment ◽  
Pet Ct ◽  
Cancer Subtype ◽  
Fdg Pet Ct ◽  
Early Metabolic Response

486 UTILITY OF 18F-FDG/PET FOR PREDICTING HISTOPATHOLOGICAL RESPONSE TO NEOADJUVANT INDUCTION CHEMOTHERAPY AND CHEMORADIOTHERAPY FOR ESOPHAGEAL AND JUNCTIONAL CARCINOMA

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Flávio Sabino ◽  
Marco Guimarães-Filho ◽  
Michel Carneiro ◽  
Luciana Ribeiro ◽  
Daniel Fernandes ◽  
...  
Keyword(s):  
Induction Chemotherapy ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Neoadjuvant Treatment ◽  
Pathologic Response ◽  
Response Evaluation ◽  
Histopathological Response ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract   Neoadjuvant treatment followed by esophagectomy is the standard therapy for patients with resectable esophageal cancer. Data have demonstrated that patients with pathologic complete response (pCR) have better survival. Several studies have been exploring whether 18F-FDG/PET performed during neoadjuvant treatment can predict a pCR, but the results are conflicting. The aim of this study was to assess the role of 18F-FDG PET/CT for predicting the histopathological response to neoadjuvant induction chemotherapy (IC) and chemoradiotherapy (CR). Methods Patients with proven squamous cell or adenocarcinoma of the esophagus or GEJ were enrolled in this prospective study. Patients received two cycles of IC with carboplatin and paclitaxel followed by concurrent CR and then esophagectomy. Metabolic response was evaluated according to PERSIST criteria by 18F-FDG PET/CT performed at baseline, at day 14 of chemotherapy and four to eight weeks after the completion of CR. Tumoral pretreatment, induction and posttreatment FDG-standardized uptake value normalized to lean body mass SULmean and percentage change were assessed. These parameters were correlated with the pathologic response using the Mandard tumor regression grade (TRG) scale. Results Thirty patients finished the IC plus CR and 16 had esophagectomy. The median age was 57 years, 75% were male and 56% had adenocarcinoma. The mean of SULmean prior to treatment, after one cycle of IC and after CR were respectively 6.12, 4.67 and 1.52. After one cycle of IC, one patient had metabolic progression, eight remained stable and seven had partial metabolic response. All metabolic responders had good histopathological response (Mandard 1 or 2). After CR, five patients had complete metabolic response (CMR). However, three of them had poor histopathological response (Mandard >2). Conclusion Our initial results suggests that the early PERSIST-based metabolic response evaluation appears useful to predict a good histopathological response. Thus, an interim 18FFDG PET/CT may help to identify good responders during the neoadjuvant treatment. However, the late metabolic response evaluation after CR had a poor pathologic correlation. In this way, a CMR after CR should not be assumed to be synonymous of complete pathologic response.

scholarly journals FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Luke S. McLean ◽  
Karda Cavanagh ◽  
Rodney J. Hicks ◽  
Jason Callahan ◽  
Jing Xie ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Complete Response ◽  
Ct Imaging ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months. Methods This was a single-centre retrospective study of 15 patients treated with cemiplimab for advanced CSCC who had CT/MRI and FDG-PET/CT at > 10 months to assess metabolic treatment response. The median age was 73 years (range 55–84) and 93% were male. RECIST1.1 and PERCIST1.0 tumor responses were evaluated by blinded readers. Results Seventy-three percent (11/15) (95%CI 44.9, 92.2%) achieved a CMR on PET. Of these 11, on RECIST1.1 there was one complete response, 9 partial responses and one stable disease. Conclusions In patients on cemiplimab for > 10 months, there was discordance between CR rates on FDG-PET versus RECIST1.1. FDG-PET/CT may have utility for clarifying depth of response in patients treated with immunotherapy for CSCC.

Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma

2007 ◽  
Author(s):  
Stefan Krüger ◽  
S. Pauls ◽  
Felix M. Mottaghy ◽  
Andreas K. Buck ◽  
Hubert Schelzig ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Pleural Mesothelioma ◽  
Pet Ct ◽  
Fdg Pet Ct

Dual Time F-18 FDG PET/CT Imaging in the Diagnosis of Renal Cell Cancer

2014 ◽  
Vol 10 (2) ◽  
pp. 134-139 ◽  
Author(s):  
Savas Karyagar ◽  
Zehra Koc ◽  
Sevda Karyagar ◽  
Tamer Ozulker ◽  
Cevat Topal ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Fdg Pet ◽  
Renal Cell ◽  
Cell Cancer ◽  
Ct Imaging ◽  
Pet Ct ◽  
Fdg Pet Ct

FDG-PET/CT Imaging of Infected Bones and Prosthetic Joints

2015 ◽  
Vol 3 (3) ◽  
pp. 225-229 ◽  
Author(s):  
Sandip Basu ◽  
Thomas C. Kwee ◽  
Soren Hess
Keyword(s):  
Fdg Pet ◽  
Ct Imaging ◽  
Prosthetic Joints ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST

2021 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Tadashi Watabe ◽  
Masatoyo Nakajo ◽  
Mana Ishibashi ◽  
Hiromitsu Daisaki ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Malignant Melanoma ◽  
Fdg Pet ◽  
Immune Checkpoint Inhibitor ◽  
Metabolic Response ◽  
Checkpoint Inhibitor ◽  
Response Evaluation ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Fdg Pet Ct

Abstract Objective In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Materials and methods Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen’s κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Results Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939–0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). Conclusions All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.

Sign in / Sign up

Export Citation Format

Share Document